SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Price & Overview
FRA:56S1 • FR0013154002
Current stock price
The current stock price of 56S1.DE is 166 EUR. Today 56S1.DE is up by 3.2%. In the past month the price decreased by -7.08%. In the past year, price decreased by -26.52%.
56S1.DE Key Statistics
- Market Cap
- 16.157B
- P/E
- 37.73
- Fwd P/E
- 31.54
- EPS (TTM)
- 4.40
- Dividend Yield
- 0.40%
56S1.DE Stock Performance
56S1.DE Stock Chart
56S1.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to 56S1.DE. When comparing the yearly performance of all stocks, 56S1.DE is a bad performer in the overall market: 91.15% of all stocks are doing better.
56S1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE. 56S1.DE has an average financial health and profitability rating.
56S1.DE Earnings
On February 3, 2026 56S1.DE reported an EPS of 1.12 and a revenue of 772.20M. The company missed EPS expectations (-12.72% surprise) and missed revenue expectations (-4.17% surprise).
56S1.DE Forecast & Estimates
19 analysts have analysed 56S1.DE and the average price target is 247.39 EUR. This implies a price increase of 49.03% is expected in the next year compared to the current price of 166.
For the next year, analysts expect an EPS growth of 19.6% and a revenue growth 7.44% for 56S1.DE
56S1.DE Groups
Sector & Classification
56S1.DE Financial Highlights
Over the last trailing twelve months 56S1.DE reported a non-GAAP Earnings per Share(EPS) of 4.4. The EPS increased by 25.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.96% | ||
| ROA | 3.33% | ||
| ROE | 6.5% | ||
| Debt/Equity | 0.49 |
56S1.DE Ownership
56S1.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| DIM | SARTORIUS STEDIM BIOTECH | 31.7 | 16.142B | ||
| SRT3 | SARTORIUS AG-VORZUG | 36.59 | 15.837B | ||
| SRT | SARTORIUS AG | 29.4 | 12.625B | ||
| QIA | QIAGEN N.V. | 15.54 | 7.102B | ||
| 1SXP | SCHOTT PHARMA AG& CO KGAA | 12.38 | 2.003B | ||
| 1EVT | EVOTEC SE | N/A | 1.501B | ||
| EVT | EVOTEC SE | N/A | 1.464B | ||
| GXI | GERRESHEIMER AG | 7.93 | 723.958M | ||
| FF | FINE FOODS & PHARMACEUTICALS | 11.95 | 180.01M | ||
| MLC | MALIN CORP PLC | N/A |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 56S1.DE
Company Profile
The company is headquartered in Aubagne, Paca and currently employs 10,098 full-time employees.
Company Info
IPO: 1994-10-20
SARTORIUS STEDIM BIOTECH
Zone Industrielle les Paluds Avenue de Jouques, Bp 1051, Aubagne Cedex
Aubagne PACA FR
Employees: 9961
Phone: 33442845600
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What does SARTORIUS STEDIM BIOTECH do?
The company is headquartered in Aubagne, Paca and currently employs 10,098 full-time employees.
Can you provide the latest stock price for SARTORIUS STEDIM BIOTECH?
The current stock price of 56S1.DE is 166 EUR. The price increased by 3.2% in the last trading session.
Does SARTORIUS STEDIM BIOTECH pay dividends?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a dividend yield of 0.4%. The yearly dividend amount is currently 0.69.
What is the ChartMill rating of SARTORIUS STEDIM BIOTECH stock?
56S1.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Would investing in SARTORIUS STEDIM BIOTECH be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 56S1.DE.
Is SARTORIUS STEDIM BIOTECH (56S1.DE) expected to grow?
The Revenue of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 7.44% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.